IPSC (Century Therapeutics) Moat Score: 3/10 (As of Jul. 08, 2026)


IPSC Century Therapeutics Inc IPSC
46 GF Score
Price $2.31
GF Value $38.91
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Century Therapeutics Moat Score?

Century Therapeutics IPSC -0.22% 46 Moat Score is 3 as of Jul. 08, 2026. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $38.91 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,393 Biotechnology companies, Century Therapeutics ranks better than 75.52% on this metric.

Century Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Century Therapeutics has No Moat: Century Therapeutics Inc has a very weak moat due to its early-stage development and lack of established market leadership or significant intellectual property. It is still developing its R&D capabilities and faces high competition in the biotech sector.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Century Therapeutics might have No Moat - Very weak/transient advantages.

Century Therapeutics  (NAS:IPSC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Century Therapeutics Moat Score Related Terms

IPSC vs PBYI, BNTC, ENTA: Moat Score Comparison

For the Biotechnology subindustry, Century Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Century Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Century Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Century Therapeutics's Moat Score falls into.


IPSC
46GF Score
Century Therapeutics Inc IPSC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Century Therapeutics (IPSC) has a Moat Score of 3 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Century Therapeutics ranks #341 out of 1393 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Century Therapeutics' Moat Score too high?
Century Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Century Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Century Therapeutics ranks #341 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' Moat Score compare to PBYI and BNTC?
According to the Biotechnology industry distribution chart, Century Therapeutics ranks #341 out of 1393 companies for Moat Score. This places Century Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Century Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Century Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Century Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $38.91, compared to a current price of $2.31 — trading 94.1% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current Moat Score is 3 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Century Therapeutics (IPSC) Overvalued in 2026?

Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued. The current stock price of $2.31 is trading 94.1% below its estimated GF Value™ of $38.91. GuruFocus considers Century Therapeutics to be Possible Value Trap.

Key valuation signals for IPSC:

  • Moat Score: 3
  • GF Value™: $38.91 vs. price of $2.31 (94.1% below fair value)
  • GF Score™: 46/100 with 3 warning signs
  • Industry Position: 50% above the Biotechnology median (#341 of 1393)

No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Century Therapeutics Business Description

Address 25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score

Get the complete analysis for IPSC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.31
Price
$38.91
GF Value